Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2015 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
Front Immunol. 2022 Mar 28;13:825367. doi: 10.3389/fimmu.2022.825367. eCollection 2022.
Front Immunol. 2022.
PMID: 35418997
Free PMC article.
OBJECTIVE: This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies patients including STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres s …
OBJECTIVE: This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK) inhibitors (jakinibs) tofacitinib and ruxolitinib in t …
Genetic analysis of leukocyte type-I interferon production and risk of coronary artery disease.
Nelson CP, Schunkert H, Samani NJ, Erridge C.
Nelson CP, et al.
Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1456-62. doi: 10.1161/ATVBAHA.114.304925. Epub 2015 Apr 16.
Arterioscler Thromb Vasc Biol. 2015.
PMID: 25882064
Free article.
These single nucleotide polymorphisms explained 27.8% of variation in the CpG-oligonucleotide-induced IFN-alpha response and were also associated with Toll-like receptor-7/8- and Toll-like receptor-9-dependent IFN-alpha and IFN-beta responses, but were not associated with inflamm …
These single nucleotide polymorphisms explained 27.8% of variation in the CpG-oligonucleotide-induced IFN-alpha response and were also assoc …
Item in Clipboard
Cite
Cite